{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T23:44:40Z","timestamp":1792626280691,"version":"4.5.0"},"reference-count":59,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2021,1,30]],"date-time":"2021-01-30T00:00:00Z","timestamp":1611964800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Mast cell disorders comprise a wide spectrum of syndromes caused by mast cells\u2019 degranulation with acute or chronic clinical manifestations. Materials and Methods: In this review article we reviewed the latest findings in scientific papers about mast cell disorders with a particular focus on mast cell activation syndrome and mastocytosis in pediatric age. Results: Patients with mast cell activation syndrome have a normal number of mast cells that are hyperreactive upon stimulation of various triggers. We tried to emphasize the diagnostic criteria, differential diagnosis, and therapeutic strategies. Another primary mast cell disorder is mastocytosis, a condition with a long-known disease, in which patients have an increased number of mast cells that accumulate in different regions of the body with different clinical evolution in pediatric age. Conclusions: Mast cell activation syndrome overlaps with different clinical entities. No consensus was found on biomarkers and no clearly resolutive treatment is available. Therefore, a more detailed knowledge of this syndrome is of fundamental importance for a correct diagnosis and effective therapy.<\/jats:p>","DOI":"10.3390\/medicina57020124","type":"journal-article","created":{"date-parts":[[2021,1,30]],"date-time":"2021-01-30T06:22:20Z","timestamp":1611987740000},"page":"124","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Mast Cell Activation Disorders"],"prefix":"10.3390","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8243-9727","authenticated-orcid":false,"given":"Arianna","family":"Giannetti","sequence":"first","affiliation":[{"name":"Pediatric Unit, IRCCS Azienda Ospedaliero-Univerisitaria di Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9358-3502","authenticated-orcid":false,"given":"Emanuele","family":"Filice","sequence":"additional","affiliation":[{"name":"Pediatric Unit, IRCCS Azienda Ospedaliero-Univerisitaria di Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7710-6995","authenticated-orcid":false,"given":"Carlo","family":"Caffarelli","sequence":"additional","affiliation":[{"name":"Clinica Pediatrica, Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampaolo","family":"Ricci","sequence":"additional","affiliation":[{"name":"Pediatric Unit, IRCCS Azienda Ospedaliero-Univerisitaria di Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0379-9562","authenticated-orcid":false,"given":"Andrea","family":"Pession","sequence":"additional","affiliation":[{"name":"Pediatric Unit, IRCCS Azienda Ospedaliero-Univerisitaria di Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,1,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Afrin, L.B., Ackerley, M.B., Bluestein, L.S., Brewer, J., Brook, J.B., Buchanan, A.D., Cuni, J.R., Davey, W.P., Dempsey, T.T., and Dorff, S.R. (2020). Diagnosis of mast cell activation syndrome: A global \u201cconsensus-2\u201d. Diagnosis.","DOI":"10.1515\/dx-2020-0005"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1056\/NEJMra1409760","article-title":"Mast Cells, Mastocytosis, and Related Disorders","volume":"373","author":"Theoharides","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1182\/blood-2007-11-078097","article-title":"Mast cells and mastocytosis","volume":"112","author":"Metcalfe","year":"2008","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/nm.2755","article-title":"IgE and mast cells in allergic disease","volume":"18","author":"Galli","year":"2012","journal-title":"Nat. Med."},{"key":"ref_5","first-page":"90","article-title":"Tryptase from human mast cells: Biochemistry, biology and clinical utility","volume":"27","author":"Schwartz","year":"1990","journal-title":"Monogr. Allergy"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/S0091-6749(05)80222-2","article-title":"Tryptase, a mediator of human mast cells","volume":"86","author":"Schwartz","year":"1990","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"11939","DOI":"10.1016\/S0021-9258(19)68496-6","article-title":"Tryptase from human pulmonary mast cells. Purification and characterization","volume":"256","author":"Schwartz","year":"1981","journal-title":"J. Biol. Chem."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"5667","DOI":"10.4049\/jimmunol.170.11.5667","article-title":"Tryptase precursors are preferentially and spontaneously released, whereas mature tryptase is retained by HMC-1 cells, mono-mac-6 cells, and human skin-derived mast cells","volume":"170","author":"Schwartz","year":"2003","journal-title":"J. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.4049\/jimmunol.176.5.3165","article-title":"The B12 anti-tryptase monoclonal antibody disrupts the tetrameric structure of heparin-stabilized betatryptase to form monomers that are inactive at neutral pH and active at acidic pH","volume":"176","author":"Fukuoka","year":"2006","journal-title":"J. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1056\/NEJM198706253162603","article-title":"Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis","volume":"316","author":"Schwartz","year":"1987","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/0091-6749(91)90238-J","article-title":"Tryptase and histamine release during aspirin-induced respiratory reactions","volume":"88","author":"Bosso","year":"1991","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1172\/JCI118337","article-title":"The alpha form of human tryptase is the predominant type present in blood at baseline in normal subjects and is elevated in those with systemic mastocytosis","volume":"96","author":"Schwartz","year":"1995","journal-title":"J. Clin. Investig."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0091-6749(95)70139-7","article-title":"Elevated serum tryptase in exercise-induced anaphylaxis","volume":"95","author":"Schwartz","year":"1995","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.iac.2006.05.010","article-title":"Diagnostic value of tryptase in anaphylaxis and mastocytosis","volume":"26","author":"Schwartz","year":"2006","journal-title":"Immunol. Allergy Clin. N. Am."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1067\/mai.2000.107600","article-title":"Histamine and tryptase levels in patients with acute allergic reactions: An emergency department\u2013based study","volume":"106","author":"Lin","year":"2000","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1172\/JCI114051","article-title":"Time course of appearance and disappearance of human mast cell tryptase in the circulation after anaphylaxis","volume":"83","author":"Schwartz","year":"1989","journal-title":"J. Clin. Investig."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"18250","DOI":"10.18632\/oncotarget.4213","article-title":"Mastocytosis: A mutated KIT receptor induced myeloproliferative disorder","volume":"6","author":"Chatterjee","year":"2015","journal-title":"Oncotarget"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000328760","article-title":"Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: A consensus proposal","volume":"157","author":"Valent","year":"2012","journal-title":"Int. Arch. Allergy Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.jaip.2019.01.006","article-title":"Proposed diagnostic algorithm for patients with suspected mast cell activation syndrome","volume":"7","author":"Valent","year":"2019","journal-title":"J. Allergy Clin. Immunol. Pr."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/pai.12681","article-title":"Asthma and allergic rhinitis in childhood: What\u2019s new","volume":"27","author":"Mastrorilli","year":"2016","journal-title":"Pediatr. Allergy Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000501079","article-title":"Why the 20% + 2 tryptase formula is a diagnostic gold standard for severe systemic mast cell activation and mast cell activation syndrome","volume":"180","author":"Valent","year":"2019","journal-title":"Int. Arch. Allergy Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.jaip.2014.06.011","article-title":"Mast cell activation syndrome: Improved identification by combined determinations of serum tryptase and 24-hour urine 11\u03b2-Prostaglandin2\u03b1","volume":"2","author":"Ravi","year":"2014","journal-title":"J. Allergy Clin. Immunol. Pr."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1073\/pnas.96.4.1609","article-title":"Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis","volume":"96","author":"Longley","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1080\/00365521.2019.1686059","article-title":"Symptoms of mast cell activation syndrome in functional gastrointestinal disorders","volume":"54","author":"Drewes","year":"2019","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.jaip.2019.08.022","article-title":"Mast cell activation syndrome: Tools for diagnosis and differential diagnosis","volume":"8","author":"Weiler","year":"2020","journal-title":"J. Allergy Clin. Immunol. Pr."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0145-2126(01)00038-8","article-title":"Diagnostic criteria and classification of mastocytosis: A consensus proposal","volume":"25","author":"Valent","year":"2001","journal-title":"Leuk. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"42","DOI":"10.2174\/1573396315666181120163952","article-title":"Childhood solitary cutaneous mastocytoma: Clinical manifestations, diagnosis, evaluation, and management","volume":"15","author":"Lam","year":"2019","journal-title":"Curr. Pediatr. Rev."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/j.jaci.2012.10.015","article-title":"Prevalence of indolent systemic mastocytosis in a Dutch region","volume":"131","author":"Arends","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jaip.2013.09.004","article-title":"The Mastocytosis Society survey on mast cell disorders: Patient experiences and perceptions","volume":"2","author":"Jennings","year":"2014","journal-title":"J Allergy Clin Immunol Pract."},{"key":"ref_30","first-page":"323","article-title":"Rare forms of urticaria","volume":"2","author":"Nettleship","year":"1869","journal-title":"Br. Med. J."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/ajh.25371","article-title":"Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management","volume":"94","author":"Pardanani","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Gurnee, E.A., Johansen, M.L., Phung, T.L., Guo, E.L., Fong, A., Tollefson, M., Nguyen, H., Brandling-Bennett, H., Moriarty, N., and Paller, A.S. (2020). Pediatric maculopapular cutaneous mastocytosis: Retrospective review of signs, symptoms, and associated conditions. Pediatr. Dermatol.","DOI":"10.1111\/pde.14399"},{"key":"ref_33","unstructured":"Macri, A., and Cook, C. (2020). Urticaria Pigmentosa. Treasure Island (FL), StatPearls Publishing."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e348","DOI":"10.1111\/pde.13651","article-title":"Diffuse cutaneous mastocytosis: Case report and literature review","volume":"35","author":"Hosking","year":"2018","journal-title":"Pediatr. Dermatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S0889-8588(05)70295-1","article-title":"Mastocytosis and the skin","volume":"14","author":"Soter","year":"2000","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jaci.2015.08.034","article-title":"Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology","volume":"137","author":"Hartmann","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1182\/blood-2016-09-731893","article-title":"Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts","volume":"129","author":"Valent","year":"2017","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.leukres.2019.04.001","article-title":"Relevant updates in systemic mastocytosis","volume":"81","author":"Coltoff","year":"2019","journal-title":"Leuk. Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e160","DOI":"10.1111\/bjh.16581","article-title":"Mast cell sarcoma with concurrent mast cell leukaemia","volume":"189","author":"Raymond","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.iac.2018.04.009","article-title":"Pediatric expression of mast cell activation disorders","volume":"38","author":"Carter","year":"2018","journal-title":"Immunol. Allergy Clin. N. Am."},{"key":"ref_41","first-page":"I","article-title":"Le sindromi da attivazione mastocitaria","volume":"34","author":"Caimmi","year":"2020","journal-title":"Riv. Immunol. Allergol. Pediatr."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.jaip.2019.02.002","article-title":"Mast cell activation syndrome and mastocytosis: Initial treatment options and long-term management","volume":"7","author":"Castells","year":"2019","journal-title":"J. Allergy Clin. Immunol. Pr."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1159\/000436969","article-title":"Management of Anesthesia in adult and pediatric mastocytosis: A Study of the Spanish Network on Mastocytosis (REMA) based on 726 anesthetic procedures","volume":"167","author":"Matito","year":"2015","journal-title":"Int. Arch. Allergy Immunol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1111\/j.1398-9995.2009.02118.x","article-title":"Mastocytosis and insect venom allergy: Diagnosis, safety and efficacy of venom immunotherapy","volume":"64","author":"Niedoszytko","year":"2009","journal-title":"Allergy"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.jaci.2018.10.063","article-title":"Adverse reactions to drugs and biologics in patients with clonal mast cell disorders: A Work Group Report of the Mast Cells Disorder Committee, American Academy of Allergy, Asthma & Immunology","volume":"143","author":"Carter","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1398-9995.2007.01569.x","article-title":"Anaphylaxis in patients with mastocytosis: A study on history, clinical features and risk factors in 120 patients","volume":"63","author":"Brockow","year":"2008","journal-title":"Allergy"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jaip.2012.08.008","article-title":"Generalized bullous eruption after routine vaccination in a child with diffuse cutaneous Mastocytosis","volume":"1","author":"Bankova","year":"2013","journal-title":"J. Allergy Clin. Immunol. Pr."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1525-1470.2008.00710.x","article-title":"Red plaque after hepatitis B vaccination","volume":"25","author":"Koh","year":"2008","journal-title":"Pediatr. Dermatol."},{"key":"ref_49","first-page":"37","article-title":"Solitary mastocytoma arising at a hepatitis B vaccination site","volume":"63","author":"Poulton","year":"1999","journal-title":"Cutis"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/pai.12647","article-title":"Evaluation of vaccination safety in children with mastocytosis","volume":"28","author":"Parente","year":"2016","journal-title":"Pediatr. Allergy Immunol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2500\/aap.2018.39.4128","article-title":"Evaluating children with suspected allergic reactions to vaccines for infectious diseases","volume":"39","author":"Franceschini","year":"2018","journal-title":"Allergy Asthma Proc."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/cea.12882","article-title":"Vaccination management in children and adults with mastocytosis","volume":"47","author":"Zanoni","year":"2017","journal-title":"Clin. Exp. Allergy"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1111\/all.12672","article-title":"H1-antihistamines for primary mast cell activation syndromes: A systematic review","volume":"70","author":"Nurmatov","year":"2015","journal-title":"Allergy"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.leukres.2011.05.006","article-title":"Tyrosine kinase inhibitors in the treatment of systemic mastocytosis","volume":"35","author":"Ustun","year":"2011","journal-title":"Leuk. Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s12185-008-0166-4","article-title":"Advanced mast cell disease: An Italian Hematological Multicenter experience","volume":"88","author":"Pagano","year":"2008","journal-title":"Int. J. Hematol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1093\/annonc\/mdx290","article-title":"Midostaurin: A magic bullet that blocks mast cell expansion and activation","volume":"28","author":"Valent","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","article-title":"Efficacy and safety of midostaurin in advanced systemic mastocytosis","volume":"374","author":"Gotlib","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0145-2126(03)00259-5","article-title":"Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: Report of five cases and review of the literature","volume":"28","author":"Hauswirth","year":"2004","journal-title":"Leuk. Res."},{"key":"ref_59","unstructured":"(2020, November 10). Cladribine. Available online: https:\/\/www.drugs.com\/international\/cladribine.html."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/57\/2\/124\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:17:30Z","timestamp":1760159850000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/57\/2\/124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,30]]},"references-count":59,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2]]}},"alternative-id":["medicina57020124"],"URL":"https:\/\/doi.org\/10.3390\/medicina57020124","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,30]]}}}